Dr. Ator earned her Ph.D. in biopsychology from the University of Maryland at College Park, a decade after Joe Brady left for Johns Hopkins School of Medicine, and completed a post-doctoral fellowship in behavioral pharmacology and substance abuse in the Division that Joe had founded in the Department of Psychiatry & Behavioral Sciences. She was invited to remain a part of the Division, and joined the faculty in 1982. In 2000, she succeeded Joe as Director of the Division. Together with colleagues in the Division, she has carried out basic research on preclinical models of drug discrimination and drug self-administration and on the relationship between discriminative and reinforcing functions of drugs. A primary research interest has been determination of the behavioral significance of GABA-A receptor subtype selectivity of novel compounds, including, more recently cognitive-behavior assessments. Recent work also has involved study of the effects of chronic administration of stimulants on behavior and development in juvenile animals. In addition to basic research funding, she served for over 10 years as the Director of a long-standing National Institute on Drug Abuse (NIDA) contract (on which Joe Brady was the original Director) to evaluate intravenous and oral self-administration of psychoactive compounds of interest to NIDA and the Drug Enforcement Administration for their abuse liability. She has carried out preclinical drug abuse liability assessments of compounds in development for pharmaceutical firms, and has served as a consultant on preclinical components of drug abuse liability evaluations with respect to Food and Drug Administration guidelines. She currently serves on the Board of Trustees of the Association for the Assessment and Accreditation of Laboratory Animal Welfare International. Dr. Ator has been the Chair of the Johns Hopkins Animal Care and Use Committee since 2001.

Andrea Grubb Barthwell, M.D., F.A.S.A.M., is a Director at Two Dreams Outer Banks, an individualized addiction treatment program rooted in the principles set forth by the American Society of Addiction Medicine (ASAM).

Two Dreams Outer Banks is a comprehensive wellness program providing individualized care for those who dream of recovering a healthy lifestyle. Two Dreams customizes an array of treatment components, therapeutic services, and recreational activities to help its guests achieve emotional peace, physical health, and personal productivity.

Two Dreams' multi-disciplinary team of physician advisors, clinicians, and other wellness professionals conducts intensive client assessments on an ongoing basis, resulting in an extraordinarily individualized and dynamic care plan. Two Dreams' guests benefit from regular physician consultations, a customized nutrition plan and detoxification diet, personal training, spa treatments, and coaching for personal success.

Dr. Barthwell has brought to the development and management of Two Dreams the experiences of a career defined by a unique balance of research and practice related to substance abuse treatment. She has focused on the impact of substance abuse on our nation's communities and on finding ways to bring innovative, leading-edge care to individuals facing today's greatest challenges. An author and lecturer on the challenges of providing effective substance abuse treatment and its connections with violence, cultural issues and infectious diseases, she has delivered thousands of hours of training to a variety of audiences.

Reflecting her commitment to merging scientific validity with practice, Dr. Barthwell has combined involvement in governmental policy with community-based work in organizations dealing with the human side of addiction. Her work with ethnic minorities, HIV/AIDS, and women with children has focused on assisting individuals to become responsible members of society. She is a former member of the National Advisory Council of the National Institute of Drug Abuse, the Center for Substance Abuse Treatment and the Drug Abuse Advisory Committee of the US. Food and Drug Administration.

President George W. Bush nominated Dr. Barthwell in December 2001 to serve as Deputy Director for Demand Reduction in the Office of National Drug Control Policy (ONDCP) and the United States Senate confirmed her on January 28, 2002. As a member of the President's sub-cabinet, Dr. Barthwell was a principal advisor in the Executive Office of the President (EOP) on policies aimed at reducing the demand for illicit drugs.

During Dr. Barthwell's tenure, ONDCP coordinated with the Center for Substance Abuse Treatment (CSAT) to provide funding for screenings, brief interventions, and referrals to treatment. In fiscal year 2004, the President's drug treatment initiative, Access to Recovery, received a $100 million appropriation from Congress. While serving in the EOP, Dr. Barthwell worked closely with the National Institute on Drug Abuse (NIDA) to define the scope of its Health Services Research portfolio.

Dr. Barthwell received a Bachelor of Arts degree in Psychology from Wesleyan University, where she recently served as an alumni elected Trustees, and a Doctor of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. Dr. Barthwell served as President of the Encounter Medical Group (EMG, an affiliate of EMGlobal), was a founding member of the Chicago Area AIDS Task Force, hosted a weekly local cable show on AIDS, and is a past president of the American Society of Addiction Medicine.

In 2003, Dr. Barthwell received the Betty Ford Award, given by the Association for Medical Education and Research in Substance Abuse. In 1997, Dr. Barthwell's peers named her one of the "Best Doctors in America" in addiction medicine.

Dr. Bigelow's research career began with IBR and with Joe Brady. He was a research assistant at IBR in 1964-65 while completing his undergraduate degree with an advanced psychology seminar with Dr. Brady at the University of Maryland. Following graduate and postdoctoral training in experimental psychology and psychopharmacology at the University of Minnesota he joined the faculty of the Johns Hopkins University School of Medicine in 1971, where he is now Director of the Behavioral Pharmacology Research Unit (BPRU), a human substance abuse and psychopharmacology research unit working both in clinical treatment research settings and in experimental clinical pharmacology laboratory settings. Dr. Bigelow's research is diverse, spanning both therapeutic and basic science settings, both behavioral and pharmacological interventions, and related to multiple varieties of substance use, abuse, and dependence, and their treatment (alcohol, tobacco, heroin, cocaine, etc.). For 30 years Dr. Bigelow has been director of the BPRU's NIDA-supported postdoctoral research training program at Johns Hopkins, which has graduated over 100 fellows, who comprise an impressive array of prominent and productive substance abuse researchers and science administrators.

Dr. Kathleen T. Brady is a board-certified psychiatrist specializing in addiction psychiatry. As a Distinguished University Professor of Psychiatry at the Medical University of South Carolina, Dr. Brady is Director of the Clinical Neuroscience Division, Director of the Women's Research Center, Director of the Southern Consortium of NIDA's Clinical Trials Network, Associate Dean of Clinical and Translational Research, and Director of the South Carolina Clinical and Translational Research Institute. Dr. Brady received her Ph.D. in Pharmacology from Virginia Commonwealth University and her M.D. degree from the Medical University of South Carolina, where she completed a residency in Psychiatry, served as Chief Resident, and completed an Addiction Psychiatry fellowship. Her research interests are in the areas of drug and alcohol abuse/addiction and comorbid conditions such as posttraumatic stress disorder and other anxiety disorders. She has served as Principal Investigator, Co-Principal Investigator, and Mentor on numerous research projects. Dr. Brady has held leadership positions in several national organizations addressing the concerns of psychiatry and addictions. She is the Psychiatry Specialty Director for the American Board of Addiction Medicine (ABAM) and serves on the ABAM Credentialing Committee; she also serves on the Human Research Committee and the Advocacy Committee of the American College of Neuropsychopharmacology (ACNP), she is a member of the Leadership Council for the Physicians and Lawyers for National Drug Policy (PLNDP). She is Past President of the Association for Medical Education and Research in Substance Abuse (AMERSA) and Past President of the American Academy of Addiction Psychiatry (AAAP). She has served on the Scientific Advisory Council of the National Institute of Drug Abuse, the Committee on Community Based Treatment of the Institute of Medicine, the National Academy of Science, and the Board of Directors of the College of Problems of Drug Dependence (CPDD). Dr. Brady also serves as an editor for several top-tier professional journals including the American Journal of Psychiatry, CNS Neuroscience and Therapeutics, the American Journal on Addictions, Drug and Alcohol Dependence, The American Journal of Drug and Alcohol Abuse, Substance Abuse and Medscape.

Silvia N. Calderon-Gutkind, Ph.D. is a Senior Scientist in the Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). As the Pharmacology Team Leader in the CDER Controlled Substance Staff, Dr. Calderon-Gutkind provides leadership to pharmacologists on policy and review issues related to the abuse liability assessment of new drug products and formulations. Since joining the FDA in 1996, she has reviewed numerous Investigational New Drug Applications (INDs) and New Drug Applications (NDAs) for drugs active in the central nervous system. She has represented the FDA as a leader and expert in the area of abuse liability assessment of drugs, and she has actively participated in the development of the recently published draft guidance for industry, Guidance for Industry: Assessment of the Abuse Potential of Drugs.

Dr. Calderon-Gutkind received her Ph.D. in Medicinal Chemistry from the University of Buenos Aires, Argentina. Her training and expertise are concentrated in the fields of medicinal chemistry and pharmacology of drugs of abuse. She began post-doctoral training as a National Research Council Fellow in the Department of Neuropsychiatry at Walter Reed Army Institute of Research (WRAIR), where she actively worked on the synthesis and development of novel anticonvulsant agents as new medications for the treatment of epilepsy and other seizure-provoking disorders. Training continued at the Addiction Research Center, National Institute of Drug Abuse, National Institutes of Health (NIH), where she specialized in chemical and biochemical aspects of drugs of abuse. She subsequently worked on the synthesis and design of potent and extremely selective novel non-peptidic delta opioid ligands at the Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH. She has numerous publications in the areas of medicinal chemistry and abuse liability assessment, holds several patents on the synthesis and pharmacological properties of novel anticonvulsants and neuroprotective agents, and review scientific-research publications for well-known journals in the field of medicinal chemistry and addiction.

Dr. H. Westley Clark, Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, leads the agency's national effort to provide effective and accessible treatment to all Americans with addictive disorders. Dr. Clark was the former chief of the Associated Substance Abuse Programs at the U.S. Department of Veterans Affairs Medical Center (DVAMC) in San Francisco, California and a former associate clinical professor, Department of Psychiatry, University of California at San Francisco (UCSF). In addition to his duties at the DVAMC, Dr. Clark served as a senior program consultant to the Robert Wood Johnson, Substance Abuse Policy Program, a co-investigator on a number of the National Institute on Drug Abuse-funded research grants in conjunction with UCSF.

Dr. Clark is a noted author and educator in substance abuse treatment, anger and pain management, psychopharmacology, and medical and legal issues. He has received numerous awards for his contributions to the field of substance abuse treatment, including a 2008 President of the United States Rank of Distinguished Executive Award in recognition of his personal commitment to excellence in government and public service; and a 2003 President of the United States of America Rank of Meritorious Executive Award in the Senior Executive Service for his sustained superior accomplishments in management of programs of the United States Government and for noteworthy achievement of quality and efficiency in the public service, 2003. In addition, he was awarded the 2008 John P. McGovern Award from the American Society of Addiction Medicine for his contributions toward increased understanding of the relationship between addiction and society.

Other awards include the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service far exceeding Departmental standards of achievement by exhibiting outstanding teamwork and timeliness on the complex task of completing the Methadone Final Rule which required coordination among several Federal agencies, 2001; Vernelle Fox Award from the California Society of Addiction Medicine for excellence in Addiction Medicine, Education and Public Service, 2000.

Dr. Clark received a B.A. in Chemistry from Wayne State University in Detroit, Michigan; he holds a Medical Degree and a Masters in Public Health from the University of Michigan, Ann Arbor; where he completed a Psychiatric Residency at University Hospital, Neuropsychiatric Institute. He obtained his Juris Doctorate from Harvard University Law School and completed a two-year Substance Abuse Fellowship at the DVAMC-SF. Dr. Clark received his board certification from the American Board of Psychiatry and Neurology in Psychiatry and sub-specialty certification in Addiction Psychiatry. Dr. Clark is licensed to practice medicine in California, Maryland, Massachusetts and Michigan. He is also a member of the Washington, D.C., Bar Association.

Aubrey C. Daniels, Ph.D., is the world's foremost authority on applying the scientifically-proven laws of human behavior to the workplace.

With business and industry confronting complex new challenges--from ethics to high turnover to outsourcing--Daniels helps the world's leading organizations employ the timeless principles of behavioral science to re-energize the workplace, optimize performance and achieve lasting results.

His management consulting firm, Aubrey Daniels International (ADI), works with business leaders such as DaimlerChrysler, Blue Cross Blue Shield, NASA, Roche Laboratories, and Westinghouse to develop management strategies that reinforce critical behaviors vital to their long-term success. Headquartered in Atlanta, the firm was founded in 1978.

Daniels is the author of four best-selling books widely recognized as international management classics: Bringing out the Best in People: How to Apply the Astonishing Power of Positive Reinforcement; Performance Management: Changing Behavior That Drives Organizational Effectiveness, and Other People's Habits and Measure of a Leader with James E. Daniels. His books have been translated into Japanese, Chinese, Korean, Spanish and French and have been licensed in China, India, Indonesia, Japan, Korea, Romania and Saudi Arabia. Look for his book, Oops! 13 Management Practices that Waste Time and Money (and what to do instead) and his current release Safe by Accident? Take the Luck out of Safety co-authored with Judy Agnew, Ph.D..

A passionate thought leader and an internationally recognized expert on management, leadership, and workplace issues, Daniels has been featured in USA Today, The Wall Street Journal, The New York Times, The Washington Post, Fortune, CNN, and CNBC.

Daniels is a member of the Board of Trustees of both Furman University and the Cambridge Center for Behavioral Studies. He is an Associate of Harvard University's John F. Kennedy School of Government, a faculty member of the College of Health Professions at the University of Florida, and a visiting professor at Florida State.

His numerous awards include the Lifetime Achievement Award from the Organizational Behavior Management Network and the Outstanding Service Award from the International Association for Behavior Analysis, which also named him a 2005 Fellow.

Daniels received his doctorate from the University of Florida, where he also earned his masters degree and was a member of Phi Beta Kappa. He received his undergraduate degree in psychology from Furman University. Daniels has been honored by both Furman University and the College of Health Professions at the University of Florida as Alumnus of the Year.

Daniels and his wife Rebecca reside in Atlanta and have two married daughters and three grandchildren.

Dr. DePaulo was founder and director of the Affective Disorders Clinic (now called the Mood Disorder Clinic) from 1977 until he became department chairman in 2002. As a faculty member in the Department of Psychiatry and Behavioral Sciences for the past 34 years, Dr. DePaulo has been a clinician, teacher, and researcher whose primary area of research has been the genetics of bipolar disorder and unipolar depression. He has devoted his career to finding the causes and new treatments for these conditions. Dr. DePaulo remains an active and sought-after clinician, teacher, and mentor.

His vision for the future of psychiatry is based his observations of the 'war' on cancer. The discovery of the causal pathways to cancer led to more rational and effective treatments. With today's molecular and imaging tools, he believes we will find the causal mechanisms to mental illness and will eventually see new ways to arrest, reverse, and prevent these devastating conditions.

David F. Dinges is a Professor of Psychology in Psychiatry, Chief of the Division of Sleep and Chronobiology, and Director of the Unit for Experimental Psychiatry in the Department of Psychiatry at the University of Pennsylvania School of Medicine. A tenured professor with more than 250 scholarly publications, Dr. Dinges is also Associate Director of Penn's Center for Sleep and Circadian Neurobiology, and a member of Penn's Institute for the Translational Medicine and Therapeutics, the Center for Functional Neuroimaging, the Penn Genomics Frontiers Institute, and the Psychology Department Graduate Group. He is a popular lecturer in Penn's medical school and in the Biological Basis of Behavior Program, and he has trained dozens of medical students, graduate students and post-doctoral fellows.

Dr. Dinges' research focuses on biological, behavioral, cognitive and psychological effects of fatigue and stress from life style, work demands, sleep loss, and disturbances of circadian biology. He has conducted extensive scientific work on development and validation of behavioral, technological, and biological interventions for these effects to promote human health and safety. His time and environmental isolation laboratory in the Hospital of the University of Pennsylvania is unique in the world for its capability to conduct prolonged study of large numbers of healthy humans in conditions that mimic challenging real world scenarios. In addition, Dr. Dinges conducts research in simulators and operational environments, including extensive research for the U.S. space program. During the past 30 years, his research has been continuously supported by major grants from the U.S. National Institutes of Health, NASA, National Space Biomedical Research Institute, Department of Defense, and other U.S. Federal agencies. He is currently measuring astronaut performance on a test he invented and deployed on the International Space Station, and evaluating crew members in a 520-day simulated Mars mission in Russia.

Dr. Dinges has served on National Academy of Sciences Committees, taught at the National Transportation Safety Board Academy, and he has advised a large number of both federal and private entities in the U.S. and abroad on scientific evidence for human performance failure in major accidents, as well as regulatory policies regarding duty hours and fatigue management. He has directed a congressionally mandated Center of Research Excellence for the Air Force Office of Scientific Research, and for the past 10 years he has led the Neurobehavioral and Psychosocial Factors Team for the NASA funded National Space Biomedical Research Institute.

He has served on the NIH Advisory Council, been President of both the U.S. Sleep Research Society and the World Federation of Sleep Research and Sleep Medicine Societies, and he has served on the Board of Directors of the American Academy of Sleep Medicine and the National Sleep Foundation. He is presently Editor-in-Chief of SLEEP, the leading scientific journal on sleep research and sleep medicine in the world.

Dr. Dinges has received numerous awards, including the 2001 Senator Mark O. Hatfield Public Policy Award from the American Academy of Sleep Medicine; the 2004 Decade of Behavior Research Award from the American Psychological Association; the 2007 NASA Distinguished Public Service Medal, which is the highest honor NASA awards to a non-Government employee; the 2008 Laurence R. Young Space Biomedical Research Award for Contributions to Human Performance in Space; and the 2009 Raymond F. Longacre Award for Outstanding Accomplishment in the Psychological and Psychiatric Aspects of Aerospace Medicine from the Aerospace Medical Association.

Christopher A. Hart is the Vice Chairman of the National Transportation Safety Board, having been nominated by President Obama and confirmed by the Senate in 2009. The NTSB investigates major transportation accidents in all modes of transportation, determines probable cause, and makes recommendations in an effort to prevent recurrences. He was previously a Member of the NTSB in 1990, having been nominated by (the first) President Bush.

Mr. Hart's previous positions have included:

• Deputy Director, Air Traffic Safety Oversight Service, Federal Aviation Administration
• Assistant Administrator for System Safety, Federal Aviation Administration
• Deputy Administrator for the National Highway Traffic Safety Administration (NHTSA)
• Deputy Assistant General Counsel to the Department of Transportation
• Managing partner of Hart & Chavers, a Washington, D.C., law firm
• Attorney with the Air Transport Association.

Mr. Hart has a law degree from Harvard Law School and a Master's Degree (magna cum laude) in Aerospace Engineering from Princeton University. He is a member of the District of Columbia Bar and the Lawyer-Pilots Bar Association, and he is a pilot with commercial, multi-engine, and instrument ratings.

Jack E. Henningfield, PhD, is Vice President, Research and Health Policy, Pinney Associates, and Professor, Adjunct, Behavioral Biology, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine. Dr. Henningfield has been on faculty at Johns Hopkins since 1978. He was director of the Robert Wood Johnson Foundation Innovators Combating Substance Abuse Awards Program at Johns Hopkins from 2002-2009, and is affiliated The Johns Hopkins Bloomberg School of Public Health. He was Chief of Clinical Pharmacology and the Abuse Potential Assessment Section of the National Institute on Drug Abuse Intramural Research Program at Johns Hopkins Bay View Campus when he left NIDA to join Pinney Associates in 1996.

Dr. Henningfield has published more than 400 research articles, reviews and book chapters, more than 10 books and monographs, and is a regulator contributor to reports by the U.S. Surgeon General, Institute of Medicine, Royal Society of Medicine of London and World Health Organization. His most recent books include Addiction and Art (2010), Addiction Treatment: Science and Policy for the Twenty-first Century (2007), and Nicotine Psychopharmacology (2009).

Dr. Henningfield presently serves on scientific advisory committees to the US Food and Drug Administration and World Health Organization addressing scientific and regulatory issues related to tobacco product design. Much of his work at Pinney Associates includes addressing the effects of pharmaceutical products may contribute to their abuse and misuse, assessing such risks, and contributing to appropriate regulation and risk management for pharmaceuticals to minimize their risks while enabling realization of their benefits for medicine and public health.

Renata J. Henry is currently the Deputy Secretary for Behavioral Health and Disabilities, at the Maryland Department of Health and Mental Hygiene. As Deputy Secretary, Ms. Henry provides executive direction to three program administrations - Mental Hygiene, Developmental Disabilities, and Alcohol and Drug Abuse. This position is created with the intention of bringing these three administrations together to better coordinate services for populations with co-occurring disorders.

Ms. Henry has over thirty years of experience in the behavioral health field, serving in various clinical and administrative positions in community-based mental health and substance abuse organizations, as well as in state and county government. Prior to becoming the Deputy Secretary, she was the director of Division of Substance Abuse and Mental Health, an operating division of Delaware Health and Social Service, where she was responsible for the administrative direction and oversight of public sector behavioral health services for adults in Delaware. During her tenure as director, she has emphasized the collaboration between systems to ensure that policy and practice are aligned to support a quality behavioral health system across the life span.

Ms. Henry strongly believes that principled and visionary leadership at all levels is critical to moving the behavioral health field into the 21st century. Ms. Henry has provided leadership at a national level in various capacities. From 2002-2006, she served a four-year term on the National Advisory Mental Health Council for the National Institutes of Health. From 2005-2007, she was the president of the board of directors of the National Association of State Mental Health Program Directors, where her agenda focused on the development of NASMHPD partnerships with other national organizations to support mental health and substance abuse system transformation.

Ms. Henry has participated on numerous committees, expert panels, and task forces, which have advised the Substance Abuse and Mental Health Services Administration (SAMHSA) on behavioral health policy, practice, financing, and cultural competence issues. She has also presented at various conferences, policy academies, and professional meetings.

Ms. Henry holds a bachelor's degree in social work from the University of Wisconsin and a master's degree in education from Antioch University. She is the mother of two wonderful daughters and says they are her greatest achievement.

Dr. Hursh directs original research and consulting efforts on fatigue, cooperative team performance, behavioral economics and drug abuse. His patented SAFTE™ (Sleep, Activity, Fatigue and Task Effectiveness) model has been accepted by the US Department of Defense as the standard warfighter fatigue model, validated and calibrated by the Department of Transportation as a fatigue risk management tool, and is currently used by the Federal Railroad Administration, the Federal Aviation Administration, and the Federal Motor Carrier Safety Administration to assess fatigue in transportation operations. He is the co-inventor of the FAST (Fatigue Avoidance and Scheduling Tool) computer application used by government agencies and industries to assess and manage fatigue. For more than 23 years, Dr. Hursh managed research in the US Army as Consultant to the Army Surgeon General for Research Psychology, Director of the Division of Neuropsychiatry at the Walter Reed Army Institute of Research, and as a medical staff officer in the Pentagon, Office of the Assistant Secretary of the Army. Dr. Hursh is also Professor of Behavioral Biology at the Johns Hopkins University School of Medicine and has more than 35 years experience as a researcher, is author of more than 65 articles, book chapters, and books, and is a former associate editor of the Journal of the Experimental Analysis of Behavior.

Dr Jerome H. Jaffe is Clinical Professor of Psychiatry, University of Maryland School of Medicine; Adjunct Professor, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health; and Senior Research Scientist at Friends Research Institute. Internationally recognized as an expert in the study of addictions, Dr. Jaffe has worked in this field in academia and government for more than fifty years as a clinician, researcher, teacher, and policymaker. He is a Distinguished Life Fellow of the American Psychiatric Association, a Fellow (Emeritus) of the American College of Neuropsychopharmacology, Founding Fellow of the American Academy of Addiction Psychiatry, Fellow of the College on Problems of Drug Dependence, and an Honorary Fellow of the Royal College of Psychiatrists and the Society for the Study of Addiction in the UK. His many published works include articles in scientific journals, chapters in major textbooks of psychiatry, pharmacology, and drug abuse, and books and articles for the lay public.

Dr. Klein has nearly forty years of experience in drug regulation and research in pharmacology and chemistry. This includes more than 20 years with the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and prior experience with the Drug Enforcement Administration (DEA). Since 2007, Dr. Klein has been Director of the Food and Drug Administration, Controlled Substance Staff (CSS), an interdisciplinary scientific team of pharmacologists, physicians, pharmacists, neuroscientists, psychologists and other biological/physical scientists. In New Drug Application review, Dr. Klein is responsible for leading the assessment of abuse liability of new drug products and providing advice on numerous public health-related concerns. In addition, Dr. Klein provides expertise in the area of post marketing review of controlled substances and coordinates activities with other USG agencies, including the National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA), the Substance Abuse Mental Health Services Administration (SAMHSA), and DEA. Dr. Klein received a B.S. in Pharmacy (1967) and Ph.D. in Medicinal Chemistry (1971) from the University of Illinois, Medical Center Campus, Chicago.

Dr. Mallis has more than 15 years experience as a leader in human factors research related to work schedules and fatigue, particularly in aviation and other transportation modes. As Chief of the NASA Fatigue Countermeasures Group at Ames Research Center for six years, Dr. Mallis was internationally recognized for her contributions to the development of innovative, practical and effective strategies to enhance safety, performance and alertness in 24/7 environments. She also served as Director of Scientific Affairs for Alertness Solutions, a private fatigue management-consulting firm, where she was responsible for all operational field research on human performance and fatigue. As Chief Scientist at IBR, Dr. Mallis continues fatigue and alertness management research through projects funded by the Federal Aviation Administration (FAA), the Civil Aerospace Medical Institute (CAMI), Transport Canada and Federal Motor Carriers Safety Administration (FMCSA), and National Aeronautics and Space Administration (NASA). Dr. Mallis received her Ph.D. in biomedical science and was a Fellow at the University of Pennsylvania under David Dinges, Ph.D., a world-renowned fatigue and performance expert. Her work has been recognized through numerous honors and awards including the Arnold D. Tuttle Award for "Original Research that has Made the Most Significant Contribution Toward the Solution of a Challenging Problem in Aerospace Medicine,? and multiple awards for her work with the Mars Exploration Rover mission.

In January 2011 Dr. McLellan returned to the University of Pennsylvania as Professor of Psychiatry and Director of the Center for Substance Abuse Solutions. He had been the Deputy Director of the White House Office of National Drug Control Policy, where he was a primary author of the president's National Drug Control Strategy. Earlier, he founded and directed the Treatment Research Institute for 17 years - an organization designed to use scientific findings combined with sound business practices to transform the substance abuse treatment system.

Dr. McLellan holds a B.A. from Colgate University and his M.S. and Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University. He has published over 400 research articles and chapters and has served as editor or editorial board member on 11 scientific journals.

Dr. McLellan is the recipient of several distinguished awards including the Life Achievement Awards of the American, British, Italian and Mexican Societies of Addiction Medicine.

Mr. Parrino has been involved in the delivery of health care and substance abuse treatment since 1974. He received both a Baccalaureate in Psychology (1974) and a Masters in Health Policy, Planning and Administration (1982) from New York University.

Mr. Parrino served as the Director of the Gramercy Park Medical Group, an outpatient methadone treatment program, from 1980 to 1994. He also served as President of the National Development and Research Institutes, Inc. (NDRI) and was the Chair of New York City's Health Systems Agency's Technical Advisory Group on Substance Abuse.

Mr. Parrino served as the Chair of the Center for Substance Abuse Treatment (CSAT) Consensus Panel for State Methadone Treatment Guidelines, the first Treatment Improvement Protocol (TIP) published for national distribution.

Currently, Mr. Parrino is the President of the American Association for the Treatment of Opioid Dependence and continues to be responsible for the development and implementation of the Association's organizing initiatives. He is a consultant and educator to government, community and business groups concerning substance abuse treatment and policy. Mr. Parrino is a recipient of the Robert Wood Johnson Foundation Innovators Award for 2003.

Thomas G. Raslear is the Staff Director of the Human Factors Research Program in the Office of Research and Development in the Federal Railroad Administration (FRA). The FRA's Human Factors Research Program addresses issues of fatigue, ergonomics, automation, accident causation (including grade crossings), organizational culture, and selection and training in the railroad industry. He is a member and former chair of the U.S. Department of Transportation's Human Factors Coordinating Committee. Recent publications include:

Hursh, S. R., Raslear, T. G., Kaye, A. S., and Fanzone, J. F. (2008). Validation and calibration of a fatigue assessment tool for railroad work schedules, final report (Report No. DOT/FRA/ORD-08/04). Washington, DC: U.S. Department of Transportation; Sussman, E. D., and Raslear, T. G. (2008). Railroad human factors. In D. A. Boehm-Davis (Ed.), Reviews of human factors and ergonomics, volume 3 (pp. 148-189). Santa Monica, CA: Human Factors and Ergonomics Society.

Prior to working at FRA, he conducted research at the Walter Reed Army Institute of Research in the areas of behavioral toxicology, chronopsychology, and comparative psychophysics. Tom has a Ph.D. and Sc.M. in Experimental Psychology from Brown University, and a B.S. (Honors in Psychology) from City College of New York.

Mr. Roberts is assigned to the Federal Aviation Administration's Air Transportation Division, Part 121 Air Carrier Operations Branch. He is responsible for flight and duty time limitations and rest requirements, fatigue risk management, and fatigue and hours of service rulemaking. He has been with the FAA for over three years and has served as a member of the U. S. Department of Transportation's Hours of Service Action Committee for all modes of transportation. He currently serves as the U.S. Member to the International Civil Aeronautics Organization Fatigue Risk Management Task Force.

Prior to coming to the FAA, Mr. Roberts served 22 years in the airline industry as a pilot conducting Part 121 operations. He has extensive experience in passenger-carrying operations along with all-cargo domestic and international long-haul operations.

Throughout his career as a pilot, Mr. Roberts has served in various positions with an airline pilot association working to improve air safety and reduce fatigue related incidents, accidents, and pilot deviations.

Mr. Roberts holds an Airline Transport Pilot certificate with several aircraft type rating, a Flight Engineer -Turbo-jet certificate, a Certified Flight Instructor certificate (CFII/MEI), and Ground Instructor certificates. He earned his BS in Business at the College of Charleston, SC.

Peter G. Roma, Ph.D., is Director of the Human Performance Laboratory at the Institutes for Behavior Resources (IBR) where he oversees the scientific development and daily operations of ongoing laboratory studies of small group behavior and performance while collaborating with other members of the IBR science team on the Institutes' fatigue, behavioral economics, and drug abuse research and consulting efforts. Dr. Roma is also Adjunct Assistant Professor of Behavioral Biology in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Adjunct Scientist in the Laboratory of Comparative Ethology at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). In addition to fatigue science and experimental behavior analysis, his broad training and interests include behavioral pharmacology, animal behavior, neuroscience, behavioral genetics, and applied statistics. Through his involvement in research over the past decade, Dr. Roma has authored or co-authored over 25 published articles and book chapters and over 50 scientific conference presentations, served as an invited peer-reviewer for 11 scientific research journals, and provided expert commentary for Discover Magazine and Scientific American.

Eric Strain is a Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, and is also the Director of the Johns Hopkins Center for Substance Abuse Treatment and Research. He maintains an active research program in substance abuse related issues, provides clinical care to patients, teaches medical students and residents, and provides administrative supervision in the maintenance of current substance abuse programs and the development of new substance abuse initiatives. In addition to these responsibilities at Hopkins, Dr. Strain has chaired a NIDA study section, is the Editor in Chief for the journal Drug and Alcohol Dependence, and is on the editorial board for several other journals. He edited, with Maxine Stitzer, the books Methadone Treatment for Opioid Dependence and The Treatment of Opioid Dependence, and with Pedro Ruiz is editing the forthcoming fifth edition of Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. He was Chair of the Food and Drug Administration's Drug Abuse Advisory Committee, and the American Psychiatric Association's Council on Addiction Psychiatry. He has served on various committees for the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, and the federal Center for Substance Abuse Treatment, and is a frequent reviewer for scientific journals in the area of substance abuse. Dr. Strain is the recipient of several competitive grant awards from the National Institute on Drug Abuse, and has published extensively on substance abuse-related matters. His research areas have included topics such as the optimal mechanisms for treating patients with substance abuse disorders, including opioid and cocaine dependence, the relationship between substance abuse and other psychiatric disorders, the abuse liability of novel opioids, and the development of new medications for substance abuse treatment. His studies have included medications such as buprenorphine, methadone and LAAM, and non-pharmacologic treatments for substance abuse disorders.

Jeffrey P. Sutton is President and Institute Director of NSBRI, a position that he has held since 2001. Dr. Sutton is also Director, Center for Space Medicine and Professor of Medicine at Baylor College of Medicine.

Dr. Sutton's education and training were at the University of Toronto and Harvard University. He holds M.D., M.Sc. (medical science/neuroscience) and Ph.D. (theoretical physics) degrees, and is a Fellow of the Royal College of Physicians of Surgeons of Canada and a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Sutton's research expertise is in smart medical systems, computational neuroscience and neuroimaging. He has made significant contributions through scholarly publications and patents to these fields, and his discoveries have given rise to three companies. His research, medical practice and teaching were integrated for more than a decade at Harvard Medical School and the Massachusetts General Hospital, where in 1995 he founded and then directed the Neural Systems Group until 2002.

In addition to serving on the Harvard faculty, Dr. Sutton has been an affiliate faculty member of the Harvard-MIT Division of Health Sciences and Technology since 1995. Between 1999 and 2002, he was the first team leader of the NSBRI Smart Medical Systems Team. In 2008, Dr. Sutton was appointed head of a new academic unit (department/center) at BCM, the Center for Space Medicine. Dr. Sutton's academic leadership is internationally acclaimed, and he has received numerous awards for his achievements, including the NASA Distinguished Public Service Medal, an NIH Career Development Award and the President's Citation from the Society of NASA Flight Surgeons.

Greg Warren is the President/CEO of Baltimore Substance Abuse Systems, Inc. or bSAS as it is commonly referred too. His organization directs the prevention, treatment and strategic planning for drug and alcohol treatment in Baltimore City. His agency oversees over 50 treatment programs serving over 21,000 individuals annually. bSAS recently was awarded a model practices award from the National Association of County and City Health Officers and two other national organizations for its buprenorphine initiative. bSAS is also recognized across the State and nationally for its innovative work in changing the way substance abuse treatment is financed in Baltimore City.

Previous to bSAS he was the Director of Substance Abuse Treatment Services for the Department of Public Safety and Correctional Services for the State of Maryland. There he was charged with expanding substance abuse treatment "behind the walls" for the 27,000 inmates incarcerated and improving the coordination and treatment of offenders as they return to their communities. Under his leadership the State prison system was awarded the first four opioid treatment program licenses in the country. He also opened five therapeutic community programs and implemented addiction assessment for all inmates in the Division of Correction.